High sensitivity CIP2A detection for oral cancer using a rapid transistor-based biosensor module

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common lip and oral cavity cancer types. It requires early detection via various medical technologies to improve the survival rate. While most detection techniques for OSCC require testing in a centralized lab to confirm cancer type, a point of care detection technique is preferred for on-site use and quick result readout. The modular biological sensor utilizing transistor-based technology has been leveraged for testing CIP2A, and optimal transistor gate voltage and load resistance for sensing setup was investigated. Sensitivities of 1 × 10−15 g/ml have been obtained for both detections of pure CIP2A protein and HeLa cell lysate using identical test conditions via serial dilution. The superior time-saving and high accuracy testing provides opportunities for rapid clinical diagnosis in the medical space.

High Sensitivity Detection of Oral Leukoplakia Comprehensive Analysis of P90 Biomarker Expression in Human Saliva and Tissue Samples

“…In addition to its commendable sensitivity, the detection method achieves a limit of detection (LOD) as low as 10 -15 g/mL while the detection range of commercial ELISA kits is limited to 0.156 to 10 ng/mL. [24] Figure 7. Output digital reading from PCB under different P90 protein concentrations.…”

“…The previous research provided confirmation of antibody functionalization through uniform methodologies, as indicated by current-voltage and capacitance measurements. [29][30][31] CIP2A Protein (MyBioSource, San Diego, CA) were diluted into series of concentration with artificial saliva (Pickering Laboratories Inc., Mountain View, CA) to establish the calibration curve. Seventeen human saliva samples and tissue samples were obtained from individuals, including both pre-oral cancer patients and healthy volunteers, through collaboration with the University of Florida Oral Pathology Clinic and Dental Clinical Research Unit.…”

“…P90, alternatively identified as KIAA1524 and Cancerous Inhibitor of PP2A (CIP2A), exhibits elevated expression levels in both oral squamous cell carcinoma (OSCC) cell lines and tissues. [22][23][24][25] This protein is of considerable interest as a promising therapeutic target or a potential diagnostic marker given the relatively low levels of CIP2A expression in normal tissues. [26] There are additional reports that implicate a positive role for protein phosphate 2A (PP2A) in inflammatory lung diseases like asthma and chronic obstructive pilmonary disease (COPD) and in heart function.…”

“…Notably, the sensitivity of this method surpasses that of commercially available ELISA test kits. [24] While exhibiting high sensitivity and a low limit of detection, it is noteworthy that the standard calibration solution used in this method is PBS, rather than artificial saliva. Furthermore, human sample testing was not conducted.…”

Sensitive Detection of Oral Leukoplakia: Analyzing P90 Biomarkers in Saliva and Tissue

“…Acknowledging these limitations emphasizes the ongoing need for research to refine existing methods and explore complementary approaches for more accurate and comprehensive oral cancer diagnostics. P90, alternatively identified as KIAA1524 and Cancerous Inhibitor of PP2A (CIP2A), exhibits elevated expression levels in both oral squamous cell carcinoma (OSCC) cell lines and tissues [22][23][24][25]. This protein is of considerable interest as a promising therapeutic target or a potential diagnostic marker, given the relatively low expression levels of CIP2A in normal tissues [26].…”